Here are the biggest calls on Wall Street on Tuesday:
Citi reiterates Nvidia as buy
Citi lowered its price target to $285 per share from $315 ahead of earnings next week. “We expect Nvidia to reiterate its prior FY28E (CY27E) revenue outlook of 70% Y/Y growth.”
Wells Fargo reiterates Nvidia as overweight
Wells lowered its price target to $300 per share from $315. “We expect NVDA to deliver solid upside in F3Q27, but more importantly provide much needed confidence in the durability of the AI investment cycle. We view supply-side production capacity scaling & visibility into CY28+ demand as key topics.”
Morgan Stanley reiterates SpaceX as overweight
Morgan Stanley said it’s sticking with the space stock. ” SpaceX is passing through ‘peak neocloud.’ Advantages in intelligence-per-watt-per-−per−second(i/w/−per−second(i/w//t) separate the winners. Heading into 2027, we expect SPCX to undergo a profound shift into robotics, mesh networks, and space-based infra.”
Cantor Fitzgerald initiates Ralph Lauren as overweight
Cantor said it sees plenty of room for growth. ” Ralph Lauren i s one of the strongest and most authentic brands in the sector, run by a premier management team that still has room to expand in all three key geographies, and it is a share-gain compounder in inclusive luxury.”
Jefferies reiterates Tesla as hold
Jefferies said a merger between SpaceX and Tesla could be more “challenging” now. “Post US mid-terms, the rationale for merging TSLA & SPCX is unchanged, but probably more challenging to implement. Q3 results demonstrated again the relative strength of underlying FCF, which is critical to support broader amb inv ambitions across Musk-led businesses.”
Jefferies upgrades Riot Platforms to buy from hold
Jefferies said the bitcoin miner and digital infrastructure company has plenty of upside ahead. “We upgrade RIOT t o BUY and raise our PT to $28 from $13.”
UBS upgrades Morgan Stanley Direct Lending Fund to buy
UBS upgraded the stock following earnings. “We upgrade MSDL to Buy from Neutral and lower our PT to $14.50 from $15.50. After reporting 3Q results late last week, shares traded lower, as several challenged credits drove a 3.8% Q/Q NAV decline.”
Goldman Sachs initiates City Therapeutics as early-state biotech
Goldman said the biotech company has a robust pipeline. “We initiate coverage on City Therapeutics (CTY) at Early-Stage Biotech. CTY is a clinical-stage biotechnology company developing RNA-interference (RNAi) therapeutics for large-market and rare disease indications.”
Rothschild & Co Redburn upgrades American Airlines to buy from neutral
The firm said it sees several positive catalysts ahead. “We upgrade American to Buy on its improved network and outer-year margin and FCF generation potential.”
BTIG initiates MongoDB as buy
BTIG said it sees long-term growth. “We are initiating coverage on MDB with a Buy rating and a $417 PT. We believe several tailwinds can support 20%+ revenue growth over the next few years.”
